✓ Translated by DotMD AI Clinical Council Source: Diabetes, obesity & metabolism • Phase III Randomized Trial

Verify Primary Source: NIH PubMed PMID #39927409 ↗

Phase III Randomized Trial: Characterization of the effect of naltrexone/bupropion on body composition (N = 82)

Original Paper Title: “Characterization of the effect of naltrexone/bupropion on body composition”

Elena Rostova (AI Quant) Rigor Score

88 / 100

Sample Size (Participants)

N = 82

Evidence Classification

Phase III Randomized Trial

Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways

NB-induced weight loss is associated with significant reductions in total percent fat mass, increase in total percent lean mass, and change in lean-to-fat mass ratio, in comparison to placebo. Larger studies are needed to further elucidate the clinical significance of these changes and impact of a potentially healthier metabolism.
Study Design & Sample: Phase III Randomized Trial published in Diabetes, obesity & metabolism (N = 82 human participants).
Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Diabetes, obesity & metabolism (2025), this phase iii randomized trial evaluating 82 human participants investigated: Oral treatment extended-release naltrexone/bupropion (NB) leads to significant weight loss, but its effect on body composition remains unclear. Key clinical takeaway: NB-induced weight loss is associated with significant reductions in total percent fat mass, increase in total percent lean mass, and change in lean-to-fat mass ratio, in comparison to placebo. Larger studies are needed to further elucidate the clinical significance of these changes and impact of a potentially healthier metabolism.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Diabetes, obesity & metabolism, 2025-05-15; N = 82; Rigor 88/100): NB-induced weight loss is associated with significant reductions in total percent fat mass, increase in total percent lean mass, and change in lean-to-fat mass ratio, in comparison to placebo. Larger studies are needed to further elucidate the clinical significance of these changes and impact of a potentially healthier metabolism.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: bupropion-naltrexone → Rx: naltrexone-hydrochloride → Rx: bupropion-xl → Rx: bupropion-hydrochloride → Condition: trichomoniasis → Condition: morbid-severe-obesity-due-to-excess-calories →

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 39927409: Phase III Randomized Trial: Characterization of the effect of naltrexone/bupropion on body composition (N = 82)

3 of 3 Free Questions Remaining